期刊文献+

吸入一氧化氮和伊洛前列素治疗婴幼儿先天性心脏病术后中重度肺动脉高压的随机对照研究 被引量:7

Comparison of inhaled nitrioxide and Iloprosin infantwith moderate osevere pulmonary hypertension af-tecardiasurgery:prospective randomized trial
原文传递
导出
摘要 目的比较吸入外源性一氧化氮(NO)和伊洛前列素(Iloprost)对先天性心脏病(先心病)术后中重度肺动脉高压(PH)的治疗效果。方法对2011年1月至2014年1月复旦大学附属儿科医院40例术后存在中重度PH的先心病患儿进行前瞻性、随机对照研究。患儿年龄为1~24个月,体质量为3.2~11.0kg。分别给予吸人NO(NO组,20例)和雾化吸入Iloprost(Iloprost组,20例)治疗。Iloprost组先吸入Iloprost10min,吸入剂量50ng/(kg·min),随之联合吸入NO20×10~10min。NO组先吸入NO20×10~10rain,随之联合吸入Iloprost10min,吸入剂量50ng/(kg·min)。检测用药前后心率、收缩压、肺动脉压(PAP)、中心静脉压等血流动力学参数。同时检测吸入NO后二氧化氮(NO:)和高铁血红蛋白(MetHb)水平。结果单纯吸入NO和Iloprost均能显著降低PAP(t=4.670,P=0.009;t=3.762,P=0.004)和肺循环/体循环压力比值(t=16.974,P=0.000;t=9.682,P=0.000),改善氧合指数,但联合应用吸入NO和Iloprost并未显示出较单纯应用更明显的效果。对PAP降低的幅度比较,吸入NO和Iloprost之间比较差异无统计学意义(F=2.742,P=0.129)。吸入NO后监测N02和MetHb水平均在正常范围内。结论吸入NO和Iloprost对先心病术后中重度PH均有显著治疗作用,二者作用效果相近。相比吸入NO的潜在毒性和所需复杂的输送监测设备,临床治疗时考虑首选合适剂量的Iloprost可能更为合理、可行。 Objective To compare the efficacy of inhaled Iloprosand nitrioxide (NO) in infantwith moderate osevere pulmonary hypertension (PH) aftecongenital heardisease surgery. MethodThiwaprospective randomized study in Children'Hospital of Fudan University from January 2011 to January 2014, including 40 in- fantwho suffered from moderate to severe PH aftehearsurgery. Theiageranged from 1 to 24 months. Theiweighranged from 3.2 to 11.0 kg. They were randomly allocated to inhale NO ( NO group, n = 20) oIlopros( Iloprosgroup,n = 20). Iloprosgroup wagiven Iloproswith 50 ng/( kg · min) fo10 min and then combined with NO 20 x 10-6 fo10 min;NO group wafirsgiven 20 x 10-6 of NO fo10 min,then combined with Ilopros50 ng/(kg· min) fo10 min. Hearrate, systoliblood pressure, pulmonary artery pressure(PAP) and central venoupressure were recor- ded continuously. Athe same time, the concentration of nitrogen dioxide and methemoglobin afteinhaling NO wade- tected. ResultInhaled Iloprosand NO caused significanreduction in PAP ( = 4. 670, P = 0. 009 ; = 3. 762, P = 0. 004) and pulmonary - to - systemipressure ratio (Pp/Ps) (= 16.974, P = 0.000 ; = 9.682, P = 0.000) busignifi- canincrease in oxygen index separately. The combination had no additional effeccompared with single application. In term of the reduction of PAP, there wano significandifference between inhaled Iloprosand NO ( F = 2. 742, P = 0. 129). The levelof nitrogen dioxide and methemoglobin were noabove the normal limits. ConclusionModerate to severe PH aftecardiasurgery wasignificantly reduced by inhaled NO and Iloprost. They had similaeffects. However, the combination of both vasodilatorfailed to prove more potenthan eithesubstance alone. Compared with the potential toxicity of NO,the individual differenceand the complex transmission, Iloprosmay be more reasonable and feasible fothe nostonerative treatmenof PH.
出处 《中华实用儿科临床杂志》 CAS CSCD 北大核心 2015年第13期1004-1007,共4页 Chinese Journal of Applied Clinical Pediatrics
关键词 心脏缺损 先天性 肺动脉高压 伊洛前列素 一氧化氮 Heardefects, congenital Pulmonary hypertension Iloprost Nitrioxide
  • 相关文献

参考文献4

二级参考文献47

  • 1Barst RJ,Langleben D,Badesch D,菅鑫妍.使用选择性内皮素A受体拮抗剂sitaxsentan治疗肺动脉高压[J].中国处方药,2006,5(8):29-29. 被引量:38
  • 2McLaughlin VV, Archer SL, Badesch DB, Barst R J, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573-1619.
  • 3Badesch DB, Abman SH, Ahearn GS, Barst R J, McCrory DC, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidencebased clinical practice guidelines. Chest 2004; 126: 35S-62S.
  • 4Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004; 25: 2243-2278.
  • 5Schrader B J, Inbar S, Kaufmann L, Vestal RE, Rich S.Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardio! 1992; 19: 1060-1064.
  • 6Jing ZC, Jiang X, Han ZY, Xu XQ, Wang Y, Wu Y, et al. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J 2009; 33: 1354-1360.
  • 7Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159: 1925-1932.
  • 8Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H, Winkler J, Borst MM, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol 2000; 35:176-182.
  • 9Hoeper MM, Lee SH, Voswinckel R, Palazzini M, Jais X, Marinelli A, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006; 48: 2546-2552.
  • 10Weir EK, Rubin L J, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Am Rev Respir Dis 1989; 140: 1623-1630.

共引文献177

同被引文献77

  • 1成革胜,张玉顺,杜亚娟,何璐,王星烨.靶向药物联合介入治疗先天性心脏病合并重度肺动脉高压的安全性及疗效[J].心血管外科杂志(电子版),2014,3(1):19-22. 被引量:9
  • 2Nold-Petry CA, Rudloff I,Baumer Y,et al. IL-32 promotes angiogen-esis[ J]. J Immunol,2014,192(2) :589-602. DOI: 10. 4049/jimmu-nol. 1202802.
  • 3Jiang Y,Nohe A, Bragdon B,et al. Trapping of BMP receptors indistinct membrane domains inhibits their function in pulmonary arte-rial hypertension [ J ]. Am J Physiol Lung Cell Mol Physiol,2011,301(2) : L218-227. DOI: http://dx. DOI. org/10. 1152/ajplung.00300.2010.
  • 4Zhao M,Austin ED,Hemnes AR,et al. An evidence-based knowl-edgebase of pulmonary arterial hypertension to identify genes andpathways relevant to pathogenesis[ J]. Mol Biosyst,2014,10(4):732-740. DOI: 0.1039/c3mb70496c.
  • 5Van Wijk B,Moorman AF, Van Den Hoff MJ. Role of bone mor-phogenetic proteins in cardiac differentiation [ J]. Cardiovasc Res,2007,74(2) :244-255. DOI: 10.1016/j. cardiores. 2006.11.022.
  • 6Kishigami S,Mishina Y. BMP signaling and early embryonic pat-terning [J]. Cytokine Growth Factor Rev, 2005,16 (3) : 265-278.DOI: 10.1016/j. cytogfr. 2005.04.002.
  • 7Miyazono K,Kamiya Y,Morikawa M. Bone morphogenetic proteinreceptors and signal transduction[ J]. J Biochem,2010,147 (1):35-51. DOI: 10.1093/jb/mvpl48.
  • 8Teichert-Kuliszewska K, Kutryk MJ, Kuliszewski MA, et al. Bonemorphogenetic protein receptor-2 signaling promotes pulmonary arte-rial endothelial cell survival : implications for loss-of-function muta-tions in the pathogenesis of pulmonary hypertension [ J ]. Circ Res,2006,98(2) :209-217.D01:10.1161/01.RES.0000200180.01710.e6.
  • 9Wei ZQ,Salmon RM,Upton PD,et al. Regulation of bone morpho-genetic protein 9(BMP9)by redox-dependent proteolysis[ J]. J BiolChem,2014,289 (45 ) : 31150-31159. DOI: 10. 1074/jbc. Ml 14.579771.
  • 10Lafyatis R. Transforming growth factor beta~at the centre of system-ic sclerosis[ J]. Nat Rev Rheumatol,2014,10(12) :706-719. DOI:10.1038/nrrheum. 2014.137.

引证文献7

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部